Are Peptides Legal in Australia? The 2026 Rules, Compound by Compound

Peptides are not illegal as a class. Many are ordinary biochemistry; insulin and oxytocin are peptides. What matters is whether a particular peptide is listed in the Poisons Standard, whether an approved product exists for it, and whether it is being supplied or used as a therapeutic good.

For the compounds people usually mean when they search this question (BPC-157, TB-500, CJC-1295, Ipamorelin, Melanotan II, retatrutide and similar), the position in 2026 is: most are Schedule 4 prescription-only substances when intended for human use; none has an approved product on the Australian Register of Therapeutic Goods (ARTG) except the GLP-1 medicines sold under brand names; and supplying or advertising them for human use without approval is unlawful. Compounds that are not named in the Poisons Standard are still unapproved therapeutic goods if they are supplied for human use.

Research-use-only supply is a different activity, governed by intended use rather than by a specific exemption. The sections below explain each part of that.

The Therapeutic Goods Administration (TGA) regulates therapeutic goods in Australia under the Therapeutic Goods Act 1989. A therapeutic good is, broadly, anything represented or likely to be taken to be for therapeutic use in humans. Medicines must be entered on the ARTG before they can be lawfully supplied, and advertising therapeutic goods to the public is tightly controlled.

Scheduling is separate. The Poisons Standard (the SUSMP, currently the June 2026 instrument, F2026L00633) classifies substances into schedules that determine how they can be supplied. Schedule 4 means prescription-only. Appendix D lists substances whose possession without authority is restricted. The states and territories give the Poisons Standard legal force through their own drugs and poisons legislation, so possession and supply offences are usually state offences while advertising and supply of unapproved goods are Commonwealth offences under the Act.

A substance can be Schedule 4 with no approved product at all. That is the position for most research peptides: prescription-only in principle, with nothing a doctor could lawfully prescribe as a registered medicine.

The entries below are as they stand in the June 2026 Poisons Standard. "Named" means the substance (or its class) appears in Schedule 4. Dates are when the entry took effect. Check the current instrument before relying on any of them; the schedules are amended several times a year.

Three things matter for peptides. First, supplying a therapeutic good that is not on the ARTG, unless an exemption applies (the Special Access Scheme and Authorised Prescriber pathways exist for doctors, not for retail). Second, advertising therapeutic goods that are not on the ARTG, or advertising prescription-only medicines to the public at all. Third, manufacturing without a licence, which the TGA has said includes "any step in the manufacturing process", such as applying a label to a blank vial or packaging product for distribution.

The penalties are substantial. The Act provides civil penalties of up to $1.82 million per breach for an individual and $18.2 million for a body corporate, and criminal penalties of up to seven years’ imprisonment for the most serious offences. In practice the TGA’s tools run from warning letters and infringement notices through product seizure and forfeiture to Federal Court proceedings.

Enforcement is not theoretical. The timeline below is drawn from TGA media releases and court records.

The Personal Importation Scheme allows an individual to import a limited quantity of a medicine for their own use or that of an immediate family member, but prescription-only medicines require a valid Australian prescription, the quantity is capped at roughly three months’ supply, and goods prohibited under customs legislation are excluded. A Schedule 4 peptide ordered from overseas without a prescription does not meet the scheme’s conditions and can be seized at the border; the BPC-157 scheduling decision was prompted partly by exactly those seizures.

Importing for commercial supply is a different matter again and requires the importer to hold the relevant approvals. Buying from an Australian supplier avoids the border question but not the supply question: the same Act applies to what happens after the parcel arrives.

Whether a product is a therapeutic good turns on what it is for. A peptide supplied for laboratory and in-vitro research, labelled as such, and not represented as being for human use, is not being supplied as a medicine. That is the basis on which research-grade peptides are sold in Australia and in most comparable jurisdictions, and it is why reputable suppliers are careful about it: no dosing guidance, no claims about effects in people, "for research purposes only, not for human consumption" on the label and the listing.

It is not a loophole. If a product is promoted, sold or bought for human use, the label does not change what it is, and the TGA’s 2026 statements make clear it will look at how products are promoted, not just how they are labelled. A buyer who intends to use a Schedule 4 peptide on themselves is outside the research framework entirely and inside the prescription-only one.

VantaLab supplies peptides for research use only. We publish a PepScan Australia certificate for every batch so that researchers can see what the vial contains, and we do not provide protocols, dosing or any advice on use in people.

For a researcher or institution sourcing peptides for laboratory work, the practical obligations are to buy from a supplier who labels and sells for research use, to keep the materials within that use, to maintain records (batch numbers and certificates of analysis), and to follow whatever institutional and state requirements apply to the work.

For anyone considering a peptide for their own use, the position is simpler and less welcome: the compounds people most often ask about are prescription-only, no registered product exists for most of them, and a doctor is the only lawful route. A GP, a pharmacist or the TGA’s own guidance are the right sources, not a supplier’s website, including this one.

Poisons Standard June 2026 (F2026L00633), Federal Register of Legislation. Therapeutic Goods Act 1989 (Cth). TGA media releases: "Unapproved peptide product promoters and suppliers are put on notice" (July 2026); "Individual issued 27 infringement notices for allegedly supplying Melanotan II" (May 2026); "TGA flexes its muscle against illegal peptides and steroids"; "TGA warning on the risks of importing unapproved peptide products". Secretary, Department of Health v Peptide Clinics Australia Pty Ltd [2019] FCA 1107. All are published at tga.gov.au and legislation.gov.au. This article was last checked against them on 27 October 2026.